Palvella Therapeutics (PVLA) Gross Margin (2014)

Palvella Therapeutics' (PVLA) quarterly Gross Margin came in at 100.0% in Q3 2014.

Palvella Therapeutics (PVLA) Gross Margin (2014) Analysis & Trends

Palvella Therapeutics (PVLA) has 1 years of Gross Margin data on file, last reported at 100.0% in Q3 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 88.95%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 86.85%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 91.79%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 90.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Palvella Therapeutics 318.78 Mn 56.92 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2014 100.00%